Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-08-05
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells. It is not yet known whether combination chemotherapy is more effective with or without
rituximab in treating aggressive non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying how well giving cyclophosphamide,
doxorubicin, vincristine, and prednisone together with or without rituximab works in treating
older patients who have aggressive non-Hodgkin's lymphoma. (This trial is no longer
randomized as of 6/2005).
Phase:
Phase 3
Details
Lead Sponsor:
German High-Grade Non-Hodgkin's Lymphoma Study Group